Pteridinone Derivatives Inhibit Non-Classical EGFR Mutations
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current EGFR inhibitors are ineffective against non-classical mutations, particularly the insertion and point mutations of exon 18-21 and ErbB2, which are prevalent in non-small cell lung cancer, leading to poor targeted therapy outcomes for patients with these mutations.
Innovation Solution
Development of pteridinone derivatives that specifically target and inhibit non-classical mutant EGFR, including point and insertion mutations of exon 18-21 and ErbB2, providing a new generation of EGFR inhibitors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If first, second and third generation EGFR inhibitors are used, then EGFR typical sensitive mutations and T790M drug-resistant mutation are inhibited, but non-classical mutations (exon 18-21 insertion mutations and ErbB2 mutations) are not inhibited
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure parameters of EGFR inhibitors to create pteridinone derivatives with novel molecular characteristics. These structural parameter changes enable the inhibitors to recognize and bind to non-classical mutant EGFR structures (exon 18-21 insertions and ErbB2 mutations) that were previously ineffective against conventional inhibitors, thereby expanding mutation type coverage while maintaining inhibitory reliability
Solution Approach 2:
The pteridinone derivative inhibitors demonstrate universality by achieving multi-functional activity against diverse EGFR mutation types. The compound structure is designed to simultaneously target classical sensitive mutations, T790M resistant mutations, and non-classical mutations including exon 18-21 insertions and ErbB2 mutations, making a single agent effective across multiple mutation categories that previously required different therapeutic approaches
2Ease of operation
If existing EGFR inhibitors are used for non-small cell lung cancer with non-classical mutations, then treatment is provided, but targeted therapy effects are poor
Solution Approach 1:
The patent resolves this contradiction by changing the chemical parameter profile of the inhibitor to match the altered binding requirements of non-classical mutant EGFR structures. The pteridinone core structure with specific substituent patterns creates optimal steric and electronic parameters for binding to insertion mutations and ErbB2 variants, transforming the inhibitor from ineffective against these mutations to highly effective, thereby improving targeted therapy efficacy while maintaining treatment availability
Data Source
AI summary
Provided is the use of a series of pteridinones and/or a pharmaceutically acceptable salt and a prodrug thereof as a non-canonical EGFR mutant inhibitor. Specifically, the present invention relates to the use of a series of compounds as represented by formula I and a pharmaceutical composition containing the series of compounds as represented by formula I in the preparation of a drug for treating a disease containing EGFR 20insX mutation, EGFR G719X mutation and ERBB2 mutation.